ClinicalTrials.gg
CompletedNCT06040086MIRANDAUpdated Jul 24, 2026

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

A Phase 3 interventional study of Placebo and Tozorakimab in Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca. Completed at 368 sites in 29 countries. Open to participants aged 40 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,454
Allocation
Randomized
Ages
40 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Enrollment
24th of 194
1,454 · median 137
Started
2023
with 6 others
Phase 3
76 of 284
4 open now
Registered
249th of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 24th largest by enrollment of the 194 interventional ones that give a count, is one of 7 that started in 2023, is one of 76 in phase 3, and was the 249th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab administered subcutaneously (SC) in adult participants with symptomatic COPD with a history of ≥ 2 moderate or ≥ 1 severe exacerbations of COPD in the 12 months prior to enrolment. Participants should be receiving optimised treatment with inhaled maintenance therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) throughout at least the last 3 months prior to enrolment.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • Chronic Obstructive Pulmonary Disease
  • COPD
  • tozorakimab
  • MEDI3506
  • exacerbations
  • ICS
  • LABA/LAMA
  • Biologic
  • Biologic Treatment
04

Who can participate

Ages eligible
40 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be ≥ 40 years of age and capable of giving signed .
  2. Documented diagnosis of for at least one year prior to enrolment.
  3. Post BD /FVC \< 0.70 and post-BD FEV1 >20% of predicted normal value
  4. Documented history of ≥ 2 moderate or ≥ 1 severe COPD exacerbations within 12 months prior to enrolment.
  5. Documented optimised inhaled dual or triple therapy for at least 3 months prior to enrolment.
  6. Smoking history of ≥ 10 pack-years.
  7. CAT total score ≥ 10, with each of the phlegm (sputum) and cough items with a score ≥ 2

Exclusion criteria

Exclusion Criteria:

  1. pulmonary disease other than .
  2. Radiological findings suggestive of a respiratory disease other than COPD that is significantly contributing to the participant's respiratory symptoms. Radiological findings of pulmonary nodules suspicious for lung cancer, as per applicable guidances, without appropriate follow up prior to randomisation. Radiological findings suggestive of acute infection.
  3. Current diagnosis of asthma, prior history of asthma, or asthma-COPD overlap. Childhood history of asthma is allowed and defined as asthma diagnosed and resolved before the age of 18
  4. Any unstable disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric disorder, major physical and/or cognitive impairment that could affect safety, study findings or participants ability to complete the study.
  5. COPD exacerbation, within 2 weeks prior to randomization, that was treated with systemic and/or antibiotics, and/or led to hospitalization.
  6. Active significant infection within the 4 weeks prior to randomization, pneumonia within 6 weeks prior to randomization, or medical condition that predisposes the participant to infection.
  7. Suspicion of, or confirmed, ongoing SARS-CoV-2 infection.
  8. Significant COVID-19 illness within the 6 months prior to enrolment.
  9. Unstable cardiovascular disorder.
  10. Diagnosis of cor pulmonale, pulmonary arterial hypertension and/or right ventricular failure.
  11. History of active severe inflammatory bowel disease or colitis within one year prior to enrolment, or unexplained diarrhoea within the 4 weeks prior to randomisation.
  12. History of known immunodeficiency disorder, including a positive test for -1 or HIV 2.
  13. History of positive test or treatment for or (except for cured hepatitis C)
  14. Evidence of active liver disease, including jaundice during screening.
  15. , current or within the past 5 years, except for adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than one year prior to enrolment. Suspected malignancy or undefined neoplasms.
  16. Participants who have evidence of active TB.
  17. History of partial or total lung resection.
  18. Scheduled major surgical procedure during the course of the study.
  19. Participants that have previously received tozorakimab.
  20. Any clinically significant abnormal findings in physical examination, vital signs, , or laboratory testing during the screening period, which in the opinion of the investigator may put the participant at risk because of their participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,454 participants (actual)

Study arms

  • Experimental
    Tozorakimab

    Dosing subcutaneously tozorakimab

    Drug: Tozorakimab

  • Placebo comparator
    Placebo

    Dosing subcutaneously with equivalent volume to tozorakimab

    Drug: Placebo

Interventions

  • DrugPlacebo

    Placebo administered subcutaneously, equivalent volume to tozorakimab throughout the study.

  • Administered subcutaneously tozorakimab and placebo throughout the study.

06

What researchers measure

Primary outcomes

  1. Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers.

    The primary endpoint will be assessed in the primary population (former smokers with symptomatic COPD and a history of exacerbations, on optimised treatment with maintenance inhaled therapy \[triple therapy, or dual therapy if triple is not considered appropriate\]).

    Time frame: Over 52 weeks

Secondary outcomes

  1. Annualized rate of moderate to severe COPD exacerbations in former or current smokers.

    The annualized rate will be assessed in the overall population of participants including current and former smokers with symptomatic COPD and history of exacerbations, on optimised treatment with maintenance inhaled therapy.

    Time frame: Over 52 weeks

  2. Change from baseline in SGRQ total score from in former smokers

    Difference in mean change from baseline in SGRQ total score in former smokers.

    Time frame: Over 52 weeks

  3. Change from baseline in SGRQ total score from in the overall population of current and former smokers.

    Difference in mean change from baseline in SGRQ total score in the overall population of current and former smokers.

    Time frame: Over 52 weeks

  4. Annualized rate of severe COPD exacerbations in former smokers

    The rate ratio of severe COPD exacerbations will be assessed in former smokers.

    Time frame: Variable duration period up to study completion, approximately 3 years

  5. Annualized rate of severe COPD exacerbations in former or current smokers

    The rate ratio of severe COPD exacerbations will be assessed in the overall population of current and former smokers.

    Time frame: Variable duration period up to study completion, approximately 3 years

  6. Change from baseline in E-RS:COPD total score in former smokers

    Difference in mean change in E-RS:COPD total score from baseline in former smokers.

    Time frame: Over 52 weeks

  7. Change from baseline in E-RS:COPD total score in former or current smokers

    Difference in mean change in E-RS:COPD total score from baseline in the overall population of current and former smokers.

    Time frame: Over 52 weeks

  8. Change from baseline in pre-bronchodilator, pre dose trough FEV1 (mL) in former smokers

    Change from baseline in pre-bronchodilator, pre dose trough FEV1 (mL) in former smokers.

    Time frame: Over 52 weeks

  9. Change from baseline in pre-bronchodilator, pre dose trough FEV1 (mL) in former or current smokers

    Change from baseline in pre-bronchodilator, pre dose trough FEV1 (mL) in the overall population of current and former smokers.

    Time frame: Over 52 weeks

  10. Change from baseline in post-bronchodilator FEV1 (mL) in former smokers

    Change from baseline in post-bronchodilator FEV1 (mL) in former smokers.

    Time frame: Week 52

  11. Change from baseline in post-bronchodilator FEV1 (mL) in former smokers or current smokers

    Change from baseline in post-bronchodilator FEV1 (mL) in former smokers or current smokers.

    Time frame: Week 52

  12. Annualised rate of COPD exacerbations requiring hospitalisations and/or Emergency Room (ER)/Emergency Department (ED) visits in former smokers

    The rate ratio of COPD exacerbations requiring hospitalisations and/or Emergency Room (ER)/Emergency Department (ED) visits in former smokers.

    Time frame: Variable duration period up to study completion, approximately 3 years

  13. Annualised rate of COPD exacerbations requiring hospitalisations and/or Emergency Room (ER)/Emergency Department (ED) visits in former or current smokers

    The rate ratio of COPD exacerbations requiring hospitalisations and/or Emergency Room (ER)/Emergency Department (ED) visits in former or current smokers.

    Time frame: Variable duration period up to study completion, approximately 3 years

  14. Change from baseline in pre-BD, pre-dose trough FEV1 (mL)

    Change from baseline in pre-BD, pre-dose trough FEV1 (mL).

    Time frame: 52 weeks

  15. Change from baseline in post-BD FEV1 (mL)

    Change from baseline in post-BD FEV1 (mL).

    Time frame: Over 52 weeks

  16. Time to first moderate to severe COPD exacerbation

    Time to first moderate to severe COPD exacerbation compared with placebo.

    Time frame: Over 52 weeks

  17. Time to first severe COPD exacerbation

    Time to first severe COPD exacerbation compared with placebo.

    Time frame: Variable duration period up to study completion, approximately 3 years

  18. Change from baseline in CAT total score

    Change from baseline in CAT total score compared with placebo.

    Time frame: Week 52

  19. Proportion of participants achieving MCID in CAT score

    Proportion of participants achieving MCID in CAT score (percentage of participants with a decrease in CAT total score of ≥ 2 points from baseline).

    Time frame: Week 52

  20. Proportion of participants achieving MCID in SGRQ total score

    Proportion of participants achieving MCID in SGRQ score (percentage of participants with a decrease in SGRQ total score of ≥ 4 points from baseline).

    Time frame: Week 52

  21. Proportion of participants achieving MCID in E-RS:COPD total score

    Proportion of participants achieving MCID in E-RS:COPD total score (percentage of participants with a decrease in E-RS:COPD total score of ≥ 2 points from baseline).

    Time frame: Week 52

  22. Annualized rate of healthcare resource utilization

    Annualized rate of healthcare resource utilization.

    Time frame: Variable duration period up to study completion, approximately 3 years

  23. Change from baseline in rescue medication

    Change from baseline (difference in mean number of puffs/day) in rescue medication use.

    Time frame: Over 52 weeks

  24. Trough serum concentrations of tozorakimab

    Pharmacokinetics: concentrations of tozorakimab in trough serum.

    Time frame: Over 52 weeks

  25. Presence of anti-drug antibodies

    Immunogenicity: presence of tozorakimab anti-drug antibodies in blood serum.

    Time frame: Over 52 weeks

  26. Time to death

    Time to death (all-cause mortality)

    Time frame: Variable duration period up to study completion, approximately 3 years

07

Study locations

368 sites
  • Research Site
    Birmingham, Alabama 35205, United States
  • Research Site
    Decatur, Alabama 35603, United States
  • Research Site
    Sheffield, Alabama 35660, United States
  • Research Site
    Phoenix, Arizona 85027, United States
  • Research Site
    Tucson, Arizona 85704, United States
  • Research Site
    Yuma, Arizona 85365, United States
  • Research Site
    Los Angeles, California 90027, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    San Francisco, California 94109, United States
  • Research Site
    Westminster, California 92683, United States
  • Research Site
    Aurora, Colorado 80014, United States
  • Research Site
    Boulder, Colorado 80301, United States
  • Research Site
    Washington D.C., District of Columbia 20037, United States
  • Research Site
    Boynton Beach, Florida 33435, United States
  • Research Site
    Cape Coral, Florida 33990, United States
  • Research Site
    Lakeland, Florida 33805, United States
  • Research Site
    Lakeland, Florida 33813, United States
  • Research Site
    Naples, Florida 34102, United States
  • Research Site
    Ocala, Florida 34470, United States
  • Research Site
    Ormond Beach, Florida 32174, United States
  • Research Site
    Atlanta, Georgia 30344, United States
  • Research Site
    Lithonia, Georgia 30038, United States
  • Research Site
    Champaign, Illinois 61820, United States
  • Research Site
    Chicago, Illinois 60607, United States
  • Research Site
    Chicago, Illinois 60616, United States
  • Research Site
    Andover, Kansas 67002, United States
  • Research Site
    Bowling Green, Kentucky 42101, United States
  • Research Site
    Lexington, Kentucky 40503, United States
  • Research Site
    Towson, Maryland 21286, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Minneapolis, Minnesota 55425, United States
  • Research Site
    Chesterfield, Missouri 63005, United States
  • Research Site
    Chesterfield, Missouri 63017, United States
  • Research Site
    Hannibal, Missouri 63401, United States
  • Research Site
    Papillion, Nebraska 68046, United States
  • Research Site
    Las Vegas, Nevada 89102, United States
  • Research Site
    Toms River, New Jersey 08755, United States
  • Research Site
    The Bronx, New York 10451, United States
  • Research Site
    Charlotte, North Carolina 28273, United States
  • Research Site
    Greenville, North Carolina 27834, United States
  • Research Site
    Huntersville, North Carolina 28078, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Dayton, Ohio 45439, United States
  • Research Site
    Lima, Ohio 45801, United States
  • Research Site
    Grants Pass, Oregon 97527, United States
  • Research Site
    Gaffney, South Carolina 29340, United States
  • Research Site
    Union, South Carolina 29379, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Elizabethton, Tennessee 37643, United States
  • Research Site
    Jackson, Tennessee 38305, United States
  • Research Site
    Dallas, Texas 75254, United States
  • Research Site
    El Paso, Texas 79902, United States
  • Research Site
    Houston, Texas 77008, United States
  • Research Site
    McKinney, Texas 75069, United States
  • Research Site
    San Antonio, Texas 78258, United States
  • Research Site
    Roy, Utah 84067, United States
  • Research Site
    Kenosha, Wisconsin 53142, United States
  • Research Site
    Buenos Aires, C1121 ABE, Argentina
  • Research Site
    CABA, C1025ABI, Argentina
  • Research Site
    CABA, C1425BEN, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1414AIF, Argentina
  • Research Site
    Córdoba, X5003DCE, Argentina
  • Research Site
    La Plata, B1904, Argentina
  • Research Site
    Mar del Plata, 7600, Argentina
  • Research Site
    Mar del Plata, B7600GWV, Argentina
  • Research Site
    Mendoza, M5500CCG, Argentina
  • Research Site
    Quilmes, B1878FNR, Argentina
  • Research Site
    San Fernando, B1646EBJ, Argentina
  • Research Site
    San Juan Bautista, 1888, Argentina
  • Research Site
    San Miguel de Tucumán, 4000, Argentina
  • Research Site
    Brussels, 1070, Belgium
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Kortrijk, 8500, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Mechelen, 2800, Belgium
  • Research Site
    Namur, 5101, Belgium
  • Research Site
    Roeselare, 8800, Belgium
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Belo Horizonte, 30150-221, Brazil
  • Research Site
    Blumenau, 89030-101, Brazil
  • Research Site
    Campina Grande do Sul, 83.430-000, Brazil
  • Research Site
    Campinas, 13060-080, Brazil
  • Research Site
    Fortaleza, 60430-270, Brazil
  • Research Site
    Porto Alegre, 90035074, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Porto Alegre, 91010-006, Brazil
  • Research Site
    São Bernardo do Campo, 09715090, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 05403-000, Brazil
  • Research Site
    Valinhos, 13271-130, Brazil
  • Research Site
    Dupnitsa, 2600, Bulgaria
  • Research Site
    Haskovo, 6300, Bulgaria
  • Research Site
    Panagyurishte, 4500, Bulgaria
  • Research Site
    Plovdiv, 4003, Bulgaria
  • Research Site
    Sofia, 1756, Bulgaria
  • Research Site
    Veliko Tanovo, 5000, Bulgaria
  • Research Site
    Yambol, 8600, Bulgaria
  • Research Site
    Calgary, Alberta T3R 1W7, Canada
  • Research Site
    Kelowna, British Columbia V1Y 4N7, Canada

Showing the first 100 of 368 sites across 29 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Watz H, Sciurba FC, Bonini M, Yanez A, Bourdin A, Zheng J, De Soyza A, Janssens W, van den Berge M, Xu JF, Saraiva GL, Jenkins M, Jimenez E, Lofdahl M, Li J, Mikosz M, Kishishita N, Jackson S, Johnson S, Patel R, Fageras M, Psallidas I. Phase III LUNA clinical programme: design of four randomised, double-blind, placebo-controlled studies assessing the efficacy and safety of tozorakimab in patients with symptomatic COPD and a high risk of exacerbations. BMJ Open Respir Res. 2026 Jul 20;13(1):e004145. doi: 10.1136/bmjresp-2026-004145. PubMed 42476723 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at : https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Mar 2026, 29 months.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 29 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2023
First posted
Sep 15, 2023
StartActual
Sep 22, 2023
Primary completionActual
Mar 6, 2026
CompletionActual
May 22, 2026
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06040086
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 15, 2023
Start date
Sep 22, 2023
Primary completion
Mar 6, 2026
Completion
May 22, 2026
Last update
Jul 24, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tozorakimab

Start the discussion